Iqvia price target raised to $300 from $240 at UBS

UBS raised the firm’s price target on Iqvia to $300 from $240 and keeps a Buy rating on the shares. The company’s Q4 results and FY24 guidance support the thesis that Iqvia’s healthy backlog and tech/data-forward offering should enable market share gains, the analyst tells investors in a research note.